CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1548 participants.

Also called NCT05508256

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,548 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05508256
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05508256. Randomized; no masking; primary purpose treatment. Start 2023-03 (anticipated); primary completion 2026-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
Acronym
CABA-HFPEF
Condition
Heart Failure With Mildly Reduced Ejection Fraction
Intervention (Device)
CE-marked Catheter Ablation
Lead sponsor
Charite University, Berlin, Germany (class: other)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)
Collaborator
Kompetenznetz Vorhofflimmern e.V. (AFNET) (class: not stated)
Collaborator
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct05508256
Content hash
17ba17bead8cabd12382b712c3024095c95bd5ad64904f614380aa5e3a3f8de4